Home>Topics>Stocks>Celgene Corporation

Celgene Corporation CELG

  1. All
  2. Commentary
  3. Fund Reports
  4. ETF Reports
  5. Headlines
    1. Why Celgene Stock Is Still A Good Investment Opportunity

      Headlines

      Tue, 26 Aug 2014

      By Arie Goren : Celgene Corporation (NASDAQ: CELG ) will continue to ..... beginning of 2013, CELG 's stock has gained ..... in my opinion, CELG 's stock still has ..... buyback. The Company Celgene Corporation , a biopharmaceutical

    2. Cramer's Mad Money - 12 Stocks That Have Performed Better Than Google (8/21/14)

      Headlines

      Fri, 22 Aug 2014

      Priceline (NASDAQ: PCLN ), Apple (NASDAQ: AAPL ), Alexion (NASDAQ: ALXN ), Regeneron (NASDAQ: REGN ), Celgene (NASDAQ: CELG ), Gilead (NASDAQ: GILD ), Netflix (NASDAQ: NFLX ), Intuitive Surgical (NASDAQ: ISRG ), Western Digital (NASDAQ

    3. U.K. cost regulator backs Revlimid for bone marrow disorders

      Headlines

      Wed, 20 Aug 2014

      U.K.'s National Institute for Health and Care Excellence reverses its position and now supports the use of Celgene's ( CELG +1.9% ) Revlimid (lenalidomide) by the National Health Service for the treatment of myelodysplastic syndromes . The healthcare

    4. Bristol-Myers and Celgene team up in cancer combo regimen

      Headlines

      Wed, 20 Aug 2014

      Bristol-Myers Squibb (NYSE: BMY ) and Celgene (NASDAQ: CELG ) collaborate in a Phase 1 clinical trial to evaluate the safety, tolerability and preliminary efficacy of a combination regimen

    5. Revlimid Phase 2 study results published in JCO

      Headlines

      Tue, 19 Aug 2014

      The results from a Phase 2 trial evaluating the safety and efficacy of Celgene's (NASDAQ: CELG ) Revlimid ( lenalidomide ) with R-CHOP as a treatment for treatment naive patients with diffuse large b-cell lymphoma (DLBCL

    6. Taking Profits From Netflix And Putting Them To Work In Celgene

      Headlines

      Mon, 18 Aug 2014

      profit at the time in the portfolio and I wanted to add shares of a biotech growth stock. I moved shares of Celgene Corporation (NASDAQ: CELG ) from my relegation league to the growth portfolio after selling Netflix. Celgene Corp is a biopharmaceutical

    7. Epizyme Holds A Key To A Potential Blockbuster Drug For Hematological Cancers

      Headlines

      Mon, 18 Aug 2014

      By Matija Snuderl : Epizyme (NASDAQ: EPZM ) is a biopharmaceutical company developing novel small molecule inhibitors targeting histone methyltransferases (HMTs). HMT inhibitors represent a new class of drugs with a paradigm shifting potential in cancer therapy, and Epizyme is currently the most ...

    8. Cramer's Mad Money - The Most Bountiful M&A Year I Have Seen (8/11/14)

      Headlines

      Tue, 12 Aug 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Monday August 11. M&A Fever: Kinder Morgan Energy Partners (NYSE: KMP ), Kinder Morgan (NYSE: KMI ), Coca-Cola (NYSE: KO ), PepsiCo (NYSE: PEP ), Kraft (NASDAQ: KRFT ), Mondelez (NASDAQ:

    9. Cramer's Mad Money - 12 Things To Watch In The Week Ahead (8/8/14)

      Headlines

      Mon, 11 Aug 2014

      By SA Editor Miriam Metzinger : Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday August 8 . 12 Things To Watch In The Week Ahead: Priceline (NASDAQ: PCLN ), Ventas (NYSE: VTR ), Kate Spade (NYSE: KATE ), Valspar (NYSE: VAL ), Macy's (NYSE: M ), Deere (NYSE: DE

    10. 2 Huge Immunology Opportunities For Celgene

      Headlines

      Thu, 7 Aug 2014

      By Cory Renauer: At about 50 times earnings, it's hard to look at Celgene (NASDAQ: CELG ) as a value opportunity, but few biotechs out there have as many growth drivers. Sales of Revlimid continue to grow at double

    « Prev12345Next »
    Content Partners